Trial Profile
A Phase I Open-label Multicentre Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs ALM 201 (Primary)
- Indications Carcinoma; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Biomarker; First in man
- Sponsors Almac Discovery
- 14 May 2022 Results assessing the safety, tolerability and pharmacokinetics of a novel anti-angiogenic peptide published in the British Journal of Cancer
- 02 Jul 2019 The trial is discontinued at UK (End Date: 23 May 2017), as per European Clinical Trials Database record.
- 02 Feb 2018 Status changed to discontinued.